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Background: Eosinophilic inflammation of the small airways is a key process in asthma that 36 
often smolders in treated patients.  The long-term effects of add-on therapy on the persistent 37 
inflammation in the small airways remain unknown.  38 
Objective: To examine the effects of add-on therapy with either ciclesonide, an inhaled 39 
corticosteroid with extrafine particles, or montelukast on small airway inflammation.  40 
Methods: Sixty patients with stable asthma receiving inhaled corticosteroid treatment were 41 
enrolled in a randomized, open-label, parallel comparison study of 24-week add-on treatment 42 
with ciclesonide or montelukast. Patients were randomly assigned to 3 groups: ciclesonide (n = 43 
19), montelukast (n = 22) and no add-on as controls (n = 19). At baseline and at weeks 4, 12 and 44 
24, extended nitric oxide analysis; pulmonary function tests, including impulse oscillometry; 45 
blood eosinophil counts; and asthma control tests (ACTs) were performed.   46 
Results: A total of 18 patients in the ciclesonide group, 19 in the montelukast group and 15 in 47 
the control group completed the study and were analysed. With repeated-measures analysis of 48 
variance, ciclesonide produced a significant decrease in alveolar nitric oxide and a significant 49 
improvement in ACT scores over time. Montelukast produced significant decreases in alveolar 50 
nitric oxide concentrations and blood eosinophil counts over time and slightly improved ACT 51 
scores, whereas no such changes were observed in the control group. Alveolar nitric oxide 52 
concentrations with ciclesonide and reactance area at low frequencies with montelukast produced 53 
greater improvements over time compared with control. 54 
Conclusions: Ciclesonide add-on therapy and montelukast add-on therapy may act differently, 55 
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 Introduction 64 
Asthma is a chronic inflammatory disease of the airways characterized by variable, recurring 65 
symptoms and reversible airflow obstruction. The immunohistopathologic features include 66 
infiltration of eosinophils and lymphocytes, mast cell activation and epithelial cell injury. To 67 
date, pathological 1, 2, physiologic 3 and radiologic findings 4 have provided sufficient evidence 68 
to support not only large but also small airways involvement in inflammation and airflow 69 





 Recently, it was found that eosinophilic inflammation of the small airways could be 71 
assessed by determining alveolar nitric oxide concentrations
7, 8
. Small airway inflammation as 72 
assessed by alveolar nitric oxide concentrations is increased in patients with refractory asthma
8
 73 
and those with nocturnal asthma 
9
 and is associated with disease severity 
10, 11
 and small airways 74 
dysfunction 
11
. Of note, 20% of asthmatic patients have increased alveolar nitric oxide 75 
concentrations despite treatments with inhaled corticosteroids (ICSs) and long-acting β2 agonists 76 
12
. Alveolar nitric oxide concentrations can also predict a future risk of disease exacerbation 
13
. 77 
These findings suggest that, even in apparently stable patients taking ICSs, additional treatment 78 
targeting the small airways may lead to reaching total asthma control. 79 
 Few studies have evaluated the changes in alveolar nitric oxide concentrations based on 80 
either an uncorrected 
7
 or corrected 
14
 model of add-on medication for persistent inflammation of 81 
the small airways. Previous studies found that oral prednisolone 
10
, but not double doses of 82 
ICSs,
8
 could decrease alveolar nitric oxide concentrations. These results suggest that alveolar 83 
nitric oxide concentrations may be resistant to a simple ICS dose elevation. In steroid-naive 84 
patients, however, extrafine particle hydrofluoroalkane–ciclesonide resulted in decreased 85 
alveolar nitric oxide concentrations 
15
 and hydrofluoroalkane–beclomethasone propionate 86 
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improved peripheral airway dysfunction 
16
. Collectively, an extrafine particle ICS is expected to 87 
decrease alveolar nitric oxide concentrations when they are used as an add-on medication. 88 
Leukotriene receptor antagonists (LTRAs) that are administered systemically are another 89 
medication that are supposed to decrease alveolar nitric oxide concentrations. Treatment with 90 
montelukast for 4 weeks improved small airway obstruction in steroid-naive patients, which 91 
resulted in a decrease in regional air trapping 
17
. So far published study data of an add-on LTRA 92 
to ICS therapy for 3 to 8  weeks with regard to alveolar nitric oxide concentrations have been 93 
conflicting
18,19
. These effects require confirmation with a longer-term study. 94 
  For this study, we hypothesized that prolonged add-on therapy to the ICS treatment with 95 
either ciclesonide or montelukast would have beneficial effects on the persistent inflammation of 96 
the small airways and would improve pulmonary function. To test this hypothesis, our primary 97 
objectives were to examine the effects of this add-on therapy on alveolar nitric oxide 98 
concentrations and to compare its effects on small airways in patients with stable asthma who 99 
had not been previously treated with extrafine particle ICSs or LTRAs. 100 
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Methods  101 
The full details of the study methods are given in the eMethods. In brief, adult patients with  102 
stable asthma who regularly visited our outpatient asthma clinic were enrolled from April 2008 103 
to August 2011. Asthma was diagnosed according to American Thoracic Society criteria 
20
. 104 
Patients were included if they were classified as being in treatment steps 2 to 5 of ICS treatment 105 
according to the Global Initiative for Asthma guidelines 
21
.  These patients had no exacerbations 106 
3 months before enrollment, had alveolar nitric oxide concentrations of 5.0 ppb or higher, and 107 
were either never-smokers or ex-smokers who had smoked fewer than 5 pack-years and had 108 
stopped more than 1 year before. The threshold level for uncorrected alveolar nitric oxide 109 
concentrations was set at 5.0 ppb; this value was the average minus 1 SD of uncorrected alveolar 110 
nitric oxide concentrations of 70 patients with asthma taking ICSs in our previous study   
22
.   111 
Exclusion criteria were current or previous use of extrafine particle ICSs or LTRAs. 112 
Patients were also excluded if, during the study period, any adverse effects of the add-on therapy 113 
or asthma exacerbations, including mild exacerbations, defined as an increased need for rescue 114 
use of short-acting β2- agonists, were noted.  115 
This study was approved by the ethics committees of our institute and was registered in 116 
UMIN Clinical Trials Registry (Registry Identified UMIN000001083). Written informed consent 117 
was obtained from all participants. 118 
 119 
Design and Measurements 120 
 This was a randomized, open-label, parallel comparison study of 24-week add-on 121 
treatment with either inhaled ciclesonide or montelukast. Patients were randomly assigned to 3 122 
treatment groups: inhaled ciclesonide, 400 μg once daily add-on (ciclesonide group); 123 
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montelukast, 10 mg once daily add-on (montelukast group); and control group, who were taking 124 
current medication only. At weeks 0 (baseline), 4, 12, and 24 (end of study period) the patients 125 
underwent extended nitric oxide analysis and pulmonary function tests, including tests with an 126 
impulse oscillometry system (IOS), spirometry, and a nitrogen single-breath wash out test. At the 127 
same time points, patients completed an asthma control test (ACT) questionnaire comprising 5 128 
questions with a best possible score of 25 
23
 and were given a rhinitis symptom score (RSS), a 129 
self-assessment questionnaire comprising 4 questions, the responses to which were ranked on a 130 
Likert-type scale with a maximum of 5 points per answer. The RSS was determined based on the 131 
Japanese Guideline for Allergic Rhinitis (best score, 20) 24 (eTable 1). 132 
  At the start and end of the study period, blood samples were obtained for blood 133 
eosinophil counts and serum high sensitivity C-reactive protein 
25
, serum eosinophil cationic 134 
protein,
26
 and serum YKL-40, a chitinase like protein 
27
. Blood samples for eosinophil cationic 135 
protein determinations were collected in SST tubes (Becton Dickinson, Mountain View, 136 
California) and were processed as previously described 
26
. YKL-40 levels were determined using 137 
an enzyme-linked immunosorbent assay kit (Quidel, San Diego, California) following the 138 
manufacturer’s instructions 27.  139 
Nitric oxide levels were determined with a chemiluminescence analyzer (NOA 280; 140 
Sievers, Boulder, Colorado) according to current guidelines, and as previously described alveolar 141 
nitric oxide concentrations are provided as noncorrected 7 and corrected values using a trumpet-142 
shaped model with axial back diffusion (eMethods) 14. 143 
After nitric oxide measurements, patients underwent prebronchodilator and 144 
postbronchodilator (ie, inhalation of 200 μg of salbutamol) pulmonary function tests.  145 
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Spirograms were obtained as recommended by the American Thoracic Society/European 146 
Respiratory Society 
28
. A nitrogen single-breath washout test was performed only before the 147 
inhalation of salbutamol to assess ventilation inhomogeneity by measuring the slope of phase 3 148 
of the nitrogen washout curve (ΔN2).  149 
Respiratory impedance was determined by IOS using a Jaeger MasterScreen, IOS
TM
 150 
(Erich Jaeger, Hoechberg Germany) that met standard recommendations (eMethods). 
16, 22
  151 
   152 
Statistical analysis  153 
For sample size determinations, we originally sought to enroll 90 patients based on previous 154 
findings 
15, 17, 19
. However, as described in the “Results” section, we decided to stop patient 155 
enrollment at 60 because of the more frequent occurrence of exacerbations in the control group, 156 
although these were mild.  157 
      Statistical analysis used JMP 6.00 (SAS Institute Inc., Cary, North Carolina) on a per-158 
protocol basis. For non-normally distributed results, comparisons were made by the Kruskal–159 
Wallis test, Fisher exact test or Wilcoxon signed-rank test as appropriate. For normally 160 
distributed results, comparisons were made by analysis of variance (ANOVA) and the paired t-161 
test. Two-way repeated-measures ANOVA was used to assess the variations among the 3 162 
treatment modalities and at different time points. For cases with unequal variations in the 163 
treatment modalities, only 1-way repeated-measures ANOVA within 1 treatment group was used. 164 
For correlation analysis, the Spearman rank-correlation test was used. Data are expressed as 165 





Enrollment, Dropout, and Exacerbation Rates and Baseline Characteristics  169 
Sixty asthmatic patients were enrolled in this study and randomly assigned to the groups: 170 
19 in the ciclesonide group, 22 in the montelukast group, and 19 in the control group (Fig 1).The 171 
reasons for patient dropout were as follows: in the ciclesonide group, 1 patient had a possible 172 
adverse effect (urticaria); in the montelukast group, 3 patients had possible adverse effects (2 173 
experienced mild gastrointestinal discomfort and they preferred to discontinue use of the 174 
medication and 1 patient had mildly elevated transaminase levels); and in the control group, 3 175 
had mild asthma exacerbations and they preferred to intensify medications and 1 patient 176 
discontinued ICS treatment following a general practitioner’s advice. As a result 18 patients in 177 
the ciclesonide group, 19 in the montelukast group, and 15 in the control group completed the 178 
study and were analyzed thereafter (Table 1). For these patients, adherence to the add-on and 179 
current medications was satisfactory, which was confirmed by 2 of the authors (H.N. and H.M.) 180 
on each visit by checking the residual number of medications. 181 
When the exacerbation frequencies were compared between the 19 patients in the control 182 
group and the 41 patients in the add-on therapy groups and assuming that the 5 patients who 183 
dropped out for reasons other than exacerbation would complete the protocol without 184 
exacerbation, the control group had a significantly higher rate of exacerbation (p = 0.03; by 185 
Fisher exact test). The baseline patient characteristics, ICS doses, and biomarkers, including 186 
fractional exhaled nitric oxide (FeNO) and alveolar nitric oxide concentrations, were not 187 
significantly different among the 3 patients who later experienced mild exacerbations and the 188 




ACT scores and RSSs 191 
By 1-way ANOVA, there was a significant improvement in ACT scores during the treatment 192 
period within the ciclesonide group (p = 0.02; Fig 2), and there was a trend for improvement 193 
within the montelukast group (p = 0.08). When subscores for the ACT components were 194 
separately analyzed in the ciclesonide group, subscores for ACT question 3 concerning nocturnal 195 
symptoms and question 5 for self-rating were marginally and insignificantly improved over time 196 
(p = 0.05 and p = 0.06, respectively). Because of the unequal variations among the 3 treatment 197 
modalities, we did not conduct 2-way ANOVA for the ACT scores. Details on ACT scores 198 
across the treatment steps are presented in eTable 2.  199 
 Among the 3 groups, neither the proportions of patients with allergic rhinitis nor their 200 
baseline RSSs differed. However, a significant difference was seen in the time trends for RSS 201 
among the 3 treatment modalities (p = 0.004; eFig 1); in particular, using 2-way ANOVA, 202 
significant differences were seen for the symptom of nasal obstruction (p = 0.046). When 203 
comparing 2 different treatment modalities in a post hoc analysis, the montelukast group 204 
exhibited a significantly better time trend for the RSS than the control group (p < 0.001) and a 205 
trend for better scores than the ciclesonide group (p = 0.07; eFig 1). A significant increase in 206 
RSS over time was found only in the montelukast group (p < 0.001, by 1-way ANOVA). 207 
 There were no associations between changes in ACT or RSS from baseline to the end of 208 
the treatment period and changes in alveolar nitric oxide concentrations or corrected alveolar 209 
nitric oxide concentrations in either treatment group. 210 
 211 
Nitric Oxide Results 212 
12 
 
No significant differences were found in the time trends for FeNO at an expiratory flow rate of 213 
50 mL/s among the 3 treatment modalities or within each of the groups (results not shown). 214 
 The time trends for uncorrected alveolar nitric oxide concentrations were significantly 215 
different among the 3 treatment groups (p = 0.048, by 2-way ANOVA). When comparing 2 216 
different treatment modalities in a post hoc analysis, the ciclesonide group had a greater decrease 217 
in alveolar nitric oxide concentrations over time than the control group (p = 0.03, by 2-way 218 
ANOVA). By 1-way ANOVA, alveolar nitric oxide concentrations in the control group did not 219 
change during the study period, whereas in both of the add-on treatment groups, alveolar nitric 220 
oxide concentrations significantly decreased over time (p = 0.01 for the ciclesonide and 221 
montelukast groups; Fig 3).  222 
 For corrected alveolar nitric oxide concentrations, 1-way ANOVA showed that there was 223 
an insignificant decrease over time in the ciclesonide group (p = 0.06). 224 
 225 
Pulmonary Function Tests 226 
None of the spirometry indices, ΔN2, or IOS indices of respiratory resistance at 5 Hz (Rrs5), 227 
respiratory resistance at 20 Hz (Rrs20), or respiratory reactance at 5 Hz (Xrs5) revealed any 228 
difference among the 3 treatment modalities during the treatment period regardless of 229 
prebronchodilator or postbronchodilator conditions. No significant changes were observed within 230 
any of the 3 groups (data not shown).  231 
 A significant difference was found in the time trends for the reactance area (AX) among 232 
the 3 treatment modalities (p = 0.04, by 2-way ANOVA). The AX levels in the montelukast 233 
group improved over time when compared with the control group (p = 0.05, by 2-way ANOVA; 234 
Fig 4). For Rrs5–Rrs20, 2-way ANOVA was not used because of the unequal variations among 235 
13 
 
the 3 treatment modalities; however, 1-way ANOVA revealed that there was a trend for a change 236 
over time in the ciclesonide group (p = 0.09). 237 
 Although there were associations between corrected alveolar nitric oxide concentrations 238 
and IOS indices of AX or Rrs5-Rrs20 at baseline (r = 0.30, p < 0.05 for both, n = 52), no 239 
associations were found between changes in pulmonary function data from baseline to the end of 240 
the treatment period and changes in alveolar nitric oxide concentrations or corrected alveolar 241 
nitric oxide concentrations in either treatment group. 242 
 243 
Blood Test Results 244 
Blood samples were obtained at baseline and at the end of the treatment period to determine 245 
blood eosinophil counts and serum levels of eosinophil cationic protein, high sensitivity C-246 
reactive protein, and YKL-40. No significant changes were found in these tests results between 247 
the beginning and the end of the treatment period, except for the montelukast group in which the 248 
eosinophil counts significantly declined after treatment (2.9 ± 2.2% at 24 weeks)(p = 0.02, paired 249 




Discussion  252 
To the best of our knowledge, this is the first long-term study that clarified the benefits and 253 
potential role of add-on therapy with either ciclesonide of extrafine particle ICS or montelukast 254 
in steroid-treated patients with stable asthma. Ciclesonide may have attenuated smoldering 255 
inflammation of the small airways and significantly improved asthma control over time. 256 
Montelukast ameliorated the remnant dysfunction of the small airways and reduced nasal 257 
symptoms and blood eosinophil counts. To a lesser extent than ciclesonide, montelukast also 258 
improved smoldering inflammation of the small airways. 259 
 Alveolar nitric oxide concentration is an established marker of small airway 260 
inflammation and is correlated with eosinophil counts in bronchoalveolar lavage fluid 
8
. In the 261 
ciclesonide group, alveolar nitric oxide concentrations significantly decreased over time when 262 
compared with the control group and the ciclesonide intragroup analysis. Our data confirmed 263 
earlier findings of the effects of 5-week treatment with ciclesonide on alveolar nitric oxide 264 
concentrations in steroid-naïve patients 
15
 and reinforced the advantage of extrafine particle ICSs 265 
to treat smoldering inflammation of the small airways, even in patients already taking ICSs. 266 
There remains the possibility that the addition of ciclesonide to the patients’ current medication 267 
may have exerted anti-inflammatory effects via the increase in the total amount of ICS, which 268 
may have suppressed the remnant inflammation throughout the airways. However, this is 269 
unlikely because FeNO at 50 mL/s did not change over time. Taken the results of the previous 270 
short-term study and current study together, ciclesonide would be capable of treating the small 271 
airways potentially because of its particles size, which was sufficiently small to reach the 272 
peripheral airways.  273 
15 
 
  In contrast to uncorrected alveolar nitric oxide concentrations, corrected alveolar nitric 274 
oxide concentrations only showed a trend toward being decreased in the ciclesonide group (p = 275 
0.06, 1-way ANOVA). Although corrected alveolar nitric oxide concentrations reflect airway 276 
dysfunction 22, 29, as do alveolar nitric oxide concentrations, corrected alveolar nitric oxide 277 
concentrations do not reflect disease severity 
14, 22
 or asthma control status 
29
. It is also not 278 
increased during asthma exacerbations in adults 
30
, a finding that is in contrast to several lines of 279 
evidence for alveolar nitric oxide concentrations. Although alveolar nitric oxide concentrations 280 
are contaminated with bronchial nitric oxide, potentially from small conducting airways where 281 
diffusion begins to replace bulk flow, our findings on alveolar nitric oxide concentrations imply 282 
that relatively small airways, albeit not actual peripheral airways, are still important in the 283 
management of asthma.  284 
 Studies of add-on medication using LTRAs that have evaluated changes in alveolar nitric 285 
oxide concentrations in persistent inflammation of the small airways reported inconsistent 286 
findings. Previous add-on studies of montelukast to fluticasone 
18
 or fluticasone and salmeterol 287 
treatment 
12
 did not find any significant benefits for montelukast with regard to decreases in 288 
alveolar nitric oxide concentrations after montelukast add-on therapy. However, these earlier 289 
studies were relatively short-term, with treatment periods of only 3 to 4 weeks. Yasui et al. 290 
investigated pranlukast use in patients with stable asthma and found significant decreases in both 291 
corrected and uncorrected alveolar nitric oxide concentrations after 8-week crossover of add-on 292 
therapy with pranlukast 19. In agreement with that study, we found that alveolar nitric oxide 293 
concentrations in the montelukast group decreased during the 24-week add-on period, although 294 
these levels were not significantly different from the control group. As with the ciclesonide 295 
group, FeNO at 50 mL/s did not change over time. These findings indicate that add-on treatment 296 
16 
 
with LTRAs for longer than 8 weeks suppresses the remnant inflammation in the small airways. 297 
In addition, our intervention study that covered the 2 seasons for allergic rhinitis (spring and 298 
autumn) provided additional evidence of the established benefit of montelukast on allergic 299 
rhinitis 
31
 and justified a role for LTRA in the therapy for patients with stable asthma with 300 
concomitant allergic rhinitis, even those with minimal symptoms.  301 
 Symptoms and airway obstruction are integral to the definition of asthma, and represent 302 
important components for assessing asthma control in both clinical practice and clinical trials. 303 
Therefore, one of the end points in our study was ACT scores. Despite the disadvantage in 304 
adherence to inhalation use, as reported previously on adherence to LTRA of 67.7% vs. 33.8% 305 
for ICS 
32
, ACT scores significantly improved over time in the ciclesonide group. In addition, 306 
there was a marginal improvement in the subscore of ACT question 3 concerning nocturnal 307 
symptoms in the ciclesonide group. To date, a number of studies have confirmed that 308 
eosinophilic inflammation worsens in patients with nocturnal asthma, particularly in the 309 
peripheral airways 
33
. Lehtimaki et al
9
 reported that nocturnal symptoms in asthmatic patients 310 
were related to higher alveolar nitric oxide concentrations. These results are in accordance with 311 
our results showing that ciclesonide add-on treatment reduced inflammation in the small airways, 312 
as assessed by alveolar nitric oxide concentrations, and improved nocturnal symptoms, as 313 
assessed by ACT subscores. Care must be taken when interpreting these findings, however, 314 
because the minimally important difference in ACT scores that reflects a clinically meaningful 315 
change is considered to be 3 points 
34
, and the increase in ACT composite scores in our 316 
ciclesonide group did not achieve this. Despite this minimal change, these statistically significant 317 
changes would still favour add-on therapy for patients with seemingly stable asthma.  318 
17 
 
 We did not find any significant changes in spirometry function results or ΔN2 between 319 
the control and therapy add-on groups, which may seem unexpected. Spirometry is not sensitive 320 
enough to detect early small airway involvement because the small airways are pathways of very 321 
low resistance and only contribute to approximately 10% of the total airway resistance 
35
. Instead 322 
of using ΔN2, ventilation heterogeneity within conductive and acinar airways could have been 323 
separately assessed using a nitrogen multiple-washout test 
36
. Another possible reason could be 324 
that our patients had already good pulmonary function, so that changes in alveolar nitric oxide 325 
concentrations were not reflected in the airway function. However, in the montelukast group, the 326 
AX
16, 22
 significantly decreased over time when compared with the control group, as was found 327 
in our previous intervention study in steroid-naïve patients 
16
. Montelukast may have reversed 328 
remodeling in the airway walls by reducing airway smooth muscle layer thickening and 329 
subepithelial fibrosis in long-term treatment, as has been shown in an animal model 37. More 330 
significant findings might be expected in extended studies in a larger number of patients. 331 
 A limitation of our study was that it was a parallel, open-label, and unblinded study, 332 
which might have influenced subjective measures, such as asthma symptoms and rescue use of 333 
short-acting β2 agonists. Another issue is the use of 2 different inhalers for corticosteroids, 334 
although we achieved good adherence in the ciclesonide group. In future studies with more 335 
patients and longer treatment periods, this issue could be resolved.  336 
In addition, we may have missed some patients with occult inflammation in the small 337 
airways by excluding those with alveolar nitric oxide concentrations less than 5 ppb, given that 338 
some patients who have high FeNO and low alveolar nitric oxide concentrations exhibit 339 
paradoxical increases in alveolar nitric oxide concentrations after treatment 38, possibly  because 340 
of dilatation of constricted small airways from terminal to respiratory bronchioles. However, by 341 
18 
 
setting this threshold for alveolar nitric oxide concentrations during patient enrollment, the 342 
changes of alveolar nitric oxide concentrations in this study could be simply interpreted.  343 
Finally, from the ethical standpoint, we stopped enrollment at 60 patients because of a 344 
higher, albeit mild, exacerbation rate in the control group, which was consistent with the finding 345 
that elevated alveolar nitric oxide concentration was associated with risk of asthma 346 
exacerbation
13
. Thus, some of the insignificant findings, particularly of the pulmonary function 347 
data in this study, may be due to lesser statistical power. Lack of associations between the 348 
changes in alveolar nitric oxide concentrations and changes in pulmonary function data or ACT 349 
scores might be another issue. However, we did not set the sample size to seek significant 350 
associations between changes in alveolar nitric oxide concentrations and any other clinical 351 
indices because of their potentially large variations during the treatment period, although 352 
alveolar nitric oxide concentrations, pulmonary function, and ACT were intuitively thought to 353 
behave in parallel. Despite these limitations, the current findings of a decrease in alveolar nitric 354 
oxide concentrations with add-on treatment are sufficient to be used as a future reference when 355 
intensifying treatment with extrafine particle ICS or LTRA add-on therapy, even in patients with 356 
seemingly stable asthma who are receiving ICS treatment but still have evidence of small 357 
airways inflammation as assessed by alveolar nitric oxide concentrations. 358 
 We conclude that ciclesonide and montelukast may act differently but that both 359 
separately can improve small airway abnormalities (eTable 3). By coadministration of these 360 
medications, cumulative effects on inflammation and small airways function can be expected and 361 
should be clarified in a future study. We can achieve additional benefits by treating inflammation 362 
of the small airways in patients with stable asthma to reach the ultimate asthma treatment goal: 363 
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Figure legends 463 
Figure 1. Registration and randomization 464 
Figure 2. Asthma control test (ACT) scores in the 3 study groups. *Significant changes in ACT 465 
scores within the ciclesonide add-on group (p = 0.02, by 1-way analysis of variance).  466 
Figure 3. Alveolar nitric oxide concentrations in the 3 study groups. *Significant difference in 467 
the time trends for alveolar nitric oxide concentrations among the 3 treatment modalities (p = 468 
0.048, by 2-way analysis of variance [ANOVA]). †Significant changes in alveolar nitric oxide 469 
concentrations in the ciclesonide add-on group (p = 0.03 vs the control group, by 2-way 470 
ANOVA) (p = 0.01, by 1-way ANOVA). ‡Significant changes within montelukast add-on group 471 
(p = 0.01, by 1-way ANOVA).  472 
Figure 4. Reactance area (AX) levels in the 3 study groups. *Significant difference in the time 473 
trends for AX levels among the 3 treatment modalities (p = 0.04, by 2-way analysis of variance 474 
[ANOVA]), †posthoc analysis between the montelukast add-on and control groups (p = 0.05, by 475 
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Table 1. Characteristics of the study patients 480 
 Ciclesonide group  Montelukast group  Control group  481 
 (n = 18) (n = 19) (n = 15) 482 
Female / male  13 / 5  13 / 6  9 / 6   483 
Age, y 64.5 ± 9.9  61.8 ± 10.6  57.4 ± 21.1   484 
Treatment Step 2/ 3/ 4/ 5
1)
  6 / 11 / 1 / 0  6 / 10 / 3 / 0  9 / 3 / 2 / 1   485 
Smoking history 486 
(never / ex-smoker) 17 / 1  15 / 4  12 / 3   487 
Atopy (yes / no) 
2)
 10 / 8  12 / 7  7 / 8   488 
Total IgE, IU/mL 120 (7-25000)  159 (8-1900)  86 (8-760)   489 
Daily dose of ICS, μg 3) 361 ± 263 353 ± 174  333 ± 222   490 
Use of LABA (yes / no) 11 /  7  10 / 9  6 / 9   491 
Use of theophylline (yes / no)  3  / 15  3  / 16  1 / 14   492 
FeNO50, ppb 42.4 ± 32.1  44.5 ± 36.4  37.5 ± 15.7   493 
Alveolar nitric oxide 494 
               concentrations, ppb   9.7 ± 5.6  8.4 ± 2.7  7.5 ± 1.6 495 
Corrected alveolar nitric oxide  496 
               concentrations, ppb 7.0 ± 5.5  5.7 ± 3.3  5.0 ± 2.0   497 
FEV1, % predicted  93.9 ± 17.5  93.7 ± 20.3  94.7 ± 23.8   498 
FEV1/FVC, %  74.7 ± 18.6  74.2 ± 18.2 73.6 ± 24.6   499 
ΔN2, % 1.8 ± 1.7  1.8 ± 1.7  2.1 ± 2.2   500 
Rrs5, kPa sL
-1
  0.43 ± 0.15 0.40 ± 0.13  0.40 ± 0.14   501 
Rrs20, kPa sL
-1
  0.35 ± 0.11  0.31 ± 0.09  0.33 ± 0.10   502 
Rrs5-Rrs20, kPa sL
-1
 0.08 ± 0.05  0.09 ± 0.07  0.07 ± 0.07   503 
Xrs5, kPa sL
-1
 -0.14 ± 0.06  -0.14 ± 0.06  -0.14 ± 0.07   504 
AX, kPa L
-1
  0.67 ± 0.51  0.78 ± 0.91  0.71± 0.68   505 
ACT score  22.7 ± 2.5  23.2 ± 2.3  23.2 ± 2.7   506 
Rhinitis symptom score  16.9 ± 2.1  16.4 ± 2.1  17.2 ± 1.7   507 
Blood eosinophils, % 5.3 ± 3.9 4.7 ± 2.9 4.0 ± 2.5  508 
Serum ECP, μg/L  16.6 ± 17.6  11.4 ± 11.1  15.0 ± 15.5   509 
Serum hsCRP, mg/dL 0.21 ± 0.37  0.10 ± 0.20  0.14 ± 0.17   510 
Serum YKL-40, ng/dL  115.2 ± 86.0  123.2 ± 83.7  93.2 ± 116.4   511 
Data are presented as number or mean ± SD, except for IgE, which is presented as median 512 
(range); p>0.05 for all characteristics according to the analysis of variance, the Kruskal-Wallis 513 
test or Fisher’s exact test. 1) According to the 2006 Global Initiative for Asthma guidelines, 2) 514 
Atopy was determined based on the presence of specific serum IgE antibodies to at least 1 515 
common inhalant allergen, including cat dander, dog dander, weed pollens, grass pollens, molds, 516 
or house dust mite, 3) equivalent to fluticasone proprionate 517 
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Adult patients with stable asthma who regularly visited our outpatient asthma clinic were 544 
enrolled from April 2008 to August 2011. Asthma was diagnosed according to American 545 
Thoracic Society criteria based on a history of recurrent episodes of wheezing and chest tightness, 546 
with or without cough, and documented airway reversibility with a bronchodilator or 547 
hyperresponsiveness to inhaled methacholine 
e1
. 548 
Nitric oxide levels were determined with a chemiluminescence analyzer (NOA 280; 549 





analyzer was daily calibrated with gas without nitric oxide and a standard concentration of 640 551 
ppb nitric oxide. Lower detection limit for nitric oxide was 2 ppb. The concentrations were 552 
determined using a data analysis program (NOA Analysis™ Software; Sievers). Seated patients 553 
inserted a mouthpiece, inhaled orally to total lung capacity, exhaled immediately against a 554 
resistance and maintained mouth pressure at 20 cm H2O, displayed on a pressure gauge. The 555 
steady-state nitric oxide plateau was taken as the fractional exhaled nitric oxide (FeNO) value. 556 
By varying expiratory resistances, we measured FeNO levels at 3 expiratory flows of 50, 100 557 
and 200 mL/s in that order.
 
Alveolar nitric oxide concentrations are provided as non-corrected
e3
 558 
and corrected values using trumpet-shaped model and axial back diffusion e2, e4. 559 
After nitric oxide measurements, patients underwent prebronchodilator and 560 
postbronchodilator (ie, inhalation of 200 μg of salbutamol) pulmonary function tests. Respiratory 561 
impedance was determined by impulse oscillometry system (IOS) followed by spirometric test 562 
and a nitrogen single-breath washout test. Forced vital capacity, forced expiratory volume in 1 563 
second, and forced midexpiratory flow were determined using a ChestGraph HI-701 spirometer 564 
(Chest MI Corp., Tokyo, Japan). Spirograms were obtained in triplicate, and the best of 3 565 
reproducible measurements was recorded, as recommended by the American Thoracic 566 
Society/European Respiratory Society e5. A nitrogen single-breath washout test was performed 567 
only before the inhalation of salbutamol to assess ventilation inhomogeneity by measuring the 568 
slope of phase 3 of the nitrogen washout curve. 569 
27 
 
Respiratory impedance was determined using a Jaeger MasterScreen, IOS (Erich Jaeger, 570 
Hoechberg Germany), which met standard recommendations 
e6
. In brief, rectangular mechanical 571 
impulses containing a continuous power spectrum ranging from 0 to 100 Hz, generated by a 572 
loudspeaker at intervals of 0.2 second, were applied to the respiratory system through a 573 
mouthpiece during tidal breathing. The resulting pressure and flow signals were measured next 574 
to the mouthpiece and were analyzed for amplitude and phase differences using a fast Fourier 575 
transform to determine respiratory resistance (Rrs) and respiratory reactance (Xrs) of the total 576 
respiratory system. To reduce loss of energy in the upper airways, the chin and cheeks were 577 
supported by the patients’ hands. As proxies for peripheral airway function, we used the negative 578 
frequency dependence of Rrs between 5 and 20 Hz (Rrs5-Rrs20), Xrs at 5 Hz (Xrs5), and 579 
reactance area (AX) that is the integral of Xrs from 5 Hz to the resonant frequency at which Xrs 580 
crosses zero 
e2,e7
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eFigure legends 608 
eFigure 1. Rhinitis symptom scores (RSS) in the 3 study groups. *Significant difference in the time trends 609 
for RSS among the 3 treatment modalities (p = 0.004, by 2-way analysis of variance [ANOVA]). 610 
†Significant changes in RSS in montelukast add-on group (p < 0.001 vs control group, by 2-way 611 

























eTable 1. 616 
Rhinitis symptom scores
 e8
 (originally in Japanese)  617 
 618 
A. Mean number of episodes of paroxysmal sneezing in a day 619 
1. ≥ 21 times 2. 20-11 times  3. 10-6 times 4. 5-1 times 5. none 620 
 621 
B. Mean number of episodes of nasal discharge a day 622 
1. ≥ 21 times 2. 20-11 times  3. 10-6 times 4. 5-1 times 5. none 623 
 624 
C. Nasal blockage 625 
1. completely obstructed all day 626 
2. severe nasal blockage causing prolonged oral breathing in a day 627 
3. severe nasal blockage causing occasional oral breathing in a day 628 
4. nasal blockage without oral breathing 629 
5. not obstructed / no symptoms  630 
 631 
D. Disturbance of daily activity (troubles with work, study, household work, sleep, going out, etc) 632 
1. impossible 633 
2. painful and complicating daily life 634 
3. intermediate between 2) and 4) 635 
4. few troubles  636 




eTable 2. Asthma control test (ACT) scores and distribution of control status at baseline according to the 639 
treatment steps   640 
 Treatment steps  
p value 2 and 3 4 and 5 
Ciclesonide 
(n = 18) 
ACT scores 
total/good/no control (n) 







(n = 19) 
ACT scores 
total/ good/no control (n) 
23.3 ± 2.4 
7/7/2 





(n = 15) 
ACT scores  
total/good/no control (n) 
23.7 ± 1.7 
5/7/0 




Data are presented as mean ± SD. 641 
Control status is defined as total when ACT score was equal to 25 points, good when ACT score was 20 642 
or higher, no control when ACT score was less than 20. 643 













FeNO NS NS NS 
Alveolar nitric oxide 
concentrations 








within the treatment modality Insignificantly 
decreased   
NS NS 




Blood eosinophils within the treatment modality NS Decreased  NS 
ACT within the treatment modality Improved  Insignificantly 
improved  
NS 
ACT: asthma control test 650 
AX: reactance area at low frequencies 651 
NS; no significant difference or no significant changes 652 
 653 
 654 
 655 
